FDA gives nod to 23andMe for no-prescription breast cancer gene testing
The Food and Drug Administration has granted 23andMe the first-ever authorization for direct-to-consumer genetic testing for cancer risk without a prescription.
A 23andMe study of genomics and weight loss seeks pathway to personalized plans to peel pounds
23andMe's weight loss study reflects the company's push to refine genomic tests by identifying genetic determinants of various diseases and chronic conditions. The study also dovetails with other companies that want to take on the country's weight management challenge with genetic testing.
presented by
The 5 Best Software to Buy for Managing a Spa Franchise
Choosing the right software translates directly into better client management, operational efficiency and growth for your spa franchise. Discover which tool is best for your business.
23andMe hears the call of therapeutics
Through its popular consumer portal, the Silicon Valley company has recruited thousands of study participants to identify genetic determinants of depression, heart disease, cancer, immunological disorders and skin diseases.
The hunt for behavioral health biomarkers is harnessing digital health at the research stage
"[Behavioral health] is a very hot topic now because we have easy access to so much more data thanks to smartphones and wearable sensors," said Dr. John Torous, co-director of the digital psychiatry program at Beth Israel Deaconess Medical Center.
The second coming of consumer genomics with 3 predictions for 2018
Several fundamentals have changed to accelerate growth in the genomics space, spurring our second look into the sector.
This is the direction direct-to-consumer genetic testing needs to take
I believe that readily accessible genetic information has the potential to improve public health if also accompanied by access to medical interpretation and counseling regarding test results.
Take the 2025 Benefit Consultant Sentiment Index Survey
If you’re helping clients navigate big changes—from the surge in GLP-1 demand to AI to the growing pressure to demonstrate ROI – we want your thoughts.
FDA allows 23andMe to reintroduce 10 genetic health risk reports for Parkinson’s, Alzheimer’s, and more
Some 3 1/2 years after having its hand slapped, 23andMe has received a green light from the FDA to market 10 direct-to-consumer genetic health risk reports for conditions such as Parkinson’s, late-onset Alzheimer’s, and celiac disease.
A new kid on the consumer genomics block
Genos, a new consumer genomics platform, officially launched on Thursday with a different approach and some unusual selling points. It's starting with whole exome sequencing, charging more, and giving customers a chance to sell their own genetic data.
23andMe integrating with Apple’s ResearchKit on iPhone
The sharing of genetic data will still be a bit complex, however - all that data will rest on 23andMe's serves, rather than on iPhones.
23andMe could sell its spit kits at Walgreens
"Soon we're going to be in Walgreens," 23andMe Chief Scientific Officer Richard Scheller reportedly said at a forum at the University of California, San Francisco. "You just buy one."
Tackling Rising Drug Costs and Growing Popularity of GLP-1’s
See how Quantum Health is providing the steps to help their members tackle the cost of specialty medications and other drugs.
23andMe enters infertility space with Celmatix partnership
23andMe and Celmatix are combining forces to understand the genomic underpinnings of infertility.
23andMe’s position on genomic diversity, international expansion
23andMe President Andy Page discusses the company's international expansion strategy - and interest in increasing the diversity of its genomics database.
These are the key players in the home health testing market
The report lists obvious choices like Quest Diagnostics, LabCorp and 23andMe - and deigns to include even Theranos, despite its recent spate of bad PR.
Highlight of #JPM16: Crowd shushes 23andMe CEO Anne Wojcicki
23andMe CEO Anne Wojcicki got a little chatty during her own company's presentation. Oops.
20 ridiculous healthcare M&A predictions (ranked from crazy to potentially legit)
The votes are in: 23AndMe is going to shock the world in 2016.